PURPOSE: To determine whether cerebral atrophy in systemic lupus erythematosus is associated with decreased levels of the neuronal marker N-acetyl-aspartic acid. METHODS: Two groups of patients with systemic lupus erythematosus were studied, those with significant atrophy (n = 11) and those without significant atrophy (n = 10), using proton MR spectroscopy on a 1.5-T imaging unit. The solvent-suppressed, short-echo, volume-localized proton spectroscopy technique showed typical brain metabolites, including N-acetylaspartate, creatine/phosphocreatine, and choline-containing compounds. RESULTS: The N-acetylaspartate-to-creatine/phosphocreatine ratio was smaller in those patients with significant cerebral atrophy (1.68 +/- 0.27) than in those patients with minimal or no atrophy (2.17 +/- .30). The degree of atrophy was negatively correlated with the N-acetylaspartate-to-creatine/phosphocreatine ratio. The choline-to-creatine/phosphocreatine ratio was not significantly altered in systemic lupus erythematosus patients with atrophy. CONCLUSION: These data suggest that cerebral atrophy in systemic lupus erythematosus is associated with neuronal dropout (or damage), which results in decreased N-acetylaspartate ratios. A change in choline ratios is not implicated in the biochemical changes associated with cerebral atrophy. Proton MR spectroscopy may be useful in correlating brain metabolites with cerebral structural changes in patients with autoimmune diseases.
PURPOSE: To determine whether cerebral atrophy in systemic lupus erythematosus is associated with decreased levels of the neuronal marker N-acetyl-aspartic acid. METHODS: Two groups of patients with systemic lupus erythematosus were studied, those with significant atrophy (n = 11) and those without significant atrophy (n = 10), using proton MR spectroscopy on a 1.5-T imaging unit. The solvent-suppressed, short-echo, volume-localized proton spectroscopy technique showed typical brain metabolites, including N-acetylaspartate, creatine/phosphocreatine, and choline-containing compounds. RESULTS: The N-acetylaspartate-to-creatine/phosphocreatine ratio was smaller in those patients with significant cerebral atrophy (1.68 +/- 0.27) than in those patients with minimal or no atrophy (2.17 +/- .30). The degree of atrophy was negatively correlated with the N-acetylaspartate-to-creatine/phosphocreatine ratio. The choline-to-creatine/phosphocreatine ratio was not significantly altered in systemic lupus erythematosuspatients with atrophy. CONCLUSION: These data suggest that cerebral atrophy in systemic lupus erythematosus is associated with neuronal dropout (or damage), which results in decreased N-acetylaspartate ratios. A change in choline ratios is not implicated in the biochemical changes associated with cerebral atrophy. Proton MR spectroscopy may be useful in correlating brain metabolites with cerebral structural changes in patients with autoimmune diseases.
Authors: Stefan C A Steens; Gerda M Steup-Beekman; Gerlof P Th Bosma; Faiza Admiraal-Behloul; Hans Olofsen; Joost Doornbos; Tom W J Huizinga; Mark A van Buchem Journal: AJNR Am J Neuroradiol Date: 2005 Nov-Dec Impact factor: 3.825
Authors: Boris Sakic; David L Kirkham; David A Ballok; James Mwanjewe; Ian M Fearon; Joseph Macri; Guanhua Yu; Michelle M Sidor; Judah A Denburg; Henry Szechtman; Jonathan Lau; Alexander K Ball; Laurie C Doering Journal: J Neuroimmunol Date: 2005-09-29 Impact factor: 3.478
Authors: Michelle M Sidor; Boris Sakic; Paul M Malinowski; David A Ballok; Curtis J Oleschuk; Joseph Macri Journal: J Neuroimmunol Date: 2005-08 Impact factor: 3.478
Authors: Rex E Jung; Judith M Segall; Rachael G Grazioplene; Clifford Qualls; Wilmer L Sibbitt; Carlos A Roldan Journal: PLoS One Date: 2010-03-24 Impact factor: 3.240
Authors: Wilmer L Sibbitt; William M Brooks; Mario Kornfeld; Blaine L Hart; Arthur D Bankhurst; Carlos A Roldan Journal: Semin Arthritis Rheum Date: 2009-10-31 Impact factor: 5.532
Authors: Hua-Xin Gao; Sean R Campbell; Min-Hui Cui; Pu Zong; Jong Hee-Hwang; Maria Gulinello; Chaim Putterman Journal: J Neuroimmunol Date: 2009-01-03 Impact factor: 3.478